NWRD06 not checked
Newish Technology (Beijing) Co., Ltd.
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “DNA plasmid delivered via IM injection + electroporation using TERESA device”In the company’s words, NCT07324304 on ClinicalTrials.gov
- Tested for
- Hepatocellular Carcinoma (HCC)
- Main trialPhase 2
- “This is a single-arm, open-label, multi-center Phase 2 clinical study to evaluate the efficacy and safety of Glypican3 (GPC3)-targeted DNA plasmid vaccine (NWRD06) in patients with GPC3-positive primary hepatocellular carcinoma after curative resection.”In the company’s words, NCT07324304 on ClinicalTrials.gov
Other drugs for Hepatocellular Carcinoma (HCC)
- CadonilimabAkeso · Phase 3
- DurvalumabAstraZeneca · Phase 3
- TremelimumabAstraZeneca · Phase 3
- BudigalimabAbbVie · Phase 2/3
- LivmoniplimabAbbVie · Phase 2/3
- BGB-B2033BeOne Medicines (BeiGene) · Phase 3
Coming up1
- 31 Dec 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 31 Dec 2028 | NWRD06 DNA Plasmid for HCC After Curative Resection. | |
| Phase 1Unknown | Dec 2024 | NWRD06 DNA Plasmid for HCC After Radical Resection |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026